The state’s CalRx Insulin Glargine will be available to consumers for a suggested retail price of $55 or less per five-pack of pens beginning Jan. 1, 2026. The insulin glargine pen agreement with ...

Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

As of January, California is the first state in the country to partner with a nonprofit to develop, produce and sell its own ...

California is the first state in the country to partner with a nonprofit to develop, produce and sell its own insulin.

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Gov. Gavin Newsom announced on Thursday that the first state-made insulin would be available at the start of 2026.California’s CalRx® Insulin Glargine in 3mL pen form will be $55 per five-pack. That's ...

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, today announced the availability of two new products: insulin glargine-yfgn ...